메뉴 건너뛰기




Volumn 28, Issue SUPPL. 1, 2011, Pages 11-16

Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events

Author keywords

Adverse events; Lenalidomide; Multiple myeloma

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BORTEZOMIB; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; VINCRISTINE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BENCE JONES PROTEIN; CALCIUM; DRUG DERIVATIVE; THALIDOMIDE;

EID: 79955646392     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0102-x     Document Type: Article
Times cited : (13)

References (26)
  • 1
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
    • (2008) Blood , vol.111 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 2
    • 33746326784 scopus 로고    scopus 로고
    • Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
    • DOI 10.1016/j.ejca.2006.01.065, PII S0959804906005466
    • Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671-1683. (Pubitemid 44118778)
    • (2006) European Journal of Cancer , vol.42 , Issue.11 , pp. 1671-1683
    • Sirohi, B.1    Powles, R.2
  • 3
    • 84868341496 scopus 로고    scopus 로고
    • Clinical Trials.gov: a service of the US National Institutes of Health. Available at: Accessed December 14, 2010
    • Clinical Trials.gov: a service of the US National Institutes of Health. Search of studies with lenalidomide and newly diagnosed multiple myeloma. Available at: http://clinicaltrials.gov/ct2/results?term= lenalidomide+and+newly+diagnosed+multiple+myeloma. Accessed December 14, 2010.
    • Search of Studies with Lenalidomide and Newly Diagnosed Multiple Myeloma
  • 4
    • 77955451933 scopus 로고    scopus 로고
    • Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches
    • Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51:1424-1443.
    • (2010) Leuk Lymphoma , vol.51 , pp. 1424-1443
    • Engelhardt, M.1    Kleber, M.2    Udi, J.3
  • 5
    • 75649085683 scopus 로고    scopus 로고
    • Current multiple myeloma treatment strategies with novel agents: A European perspective
    • Ludwig H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15:6-25.
    • (2010) Oncologist , vol.15 , pp. 6-25
    • Ludwig, H.1    Beksac, M.2    Bladé, J.3
  • 6
    • 36349010285 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Multiple Myeloma (009) Study Investigators
    • Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
    • (2007) N Engl J Med , vol.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 7
    • 36349023319 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Multiple Myeloma (010) Study Investigators
    • Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
    • (2007) N Engl J Med , vol.357 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3
  • 8
    • 67649985917 scopus 로고    scopus 로고
    • Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    • Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164-170.
    • (2009) Br J Haematol , vol.146 , pp. 164-170
    • Chen, C.1    Reece, D.E.2    Siegel, D.3
  • 9
    • 65349097489 scopus 로고    scopus 로고
    • Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
    • Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426-432.
    • (2009) Eur J Haematol , vol.82 , pp. 426-432
    • Stadtmauer, E.A.1    Weber, D.M.2    Niesvizky, R.3
  • 10
    • 77949463293 scopus 로고    scopus 로고
    • Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone
    • ASH Annual Meeting Abstracts
    • Ishak J, Dimopoulus MA, Weber D, Knight RD, Shearer A, Caro J. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting Abstracts). 2008;112:3708.
    • (2008) Blood , vol.112 , pp. 3708
    • Ishak, J.1    Dimopoulus, M.A.2    Weber, D.3    Knight, R.D.4    Shearer, A.5    Caro, J.6
  • 11
    • 73249146496 scopus 로고    scopus 로고
    • Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An openlabel randomised controlled trial
    • Eastern Cooperative Oncology Group
    • Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME. Eastern Cooperative Oncology Group. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an openlabel randomised controlled trial. Lancet Oncol. 2010;11:29-37.
    • (2010) Lancet Oncol , vol.11 , pp. 29-37
    • Rajkumar, S.V.1    Jacobus, S.2    Callander, N.S.3    Fonseca, R.4    Vesole, D.H.5    Williams, M.E.6
  • 13
    • 66149109580 scopus 로고    scopus 로고
    • Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
    • Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113:4137-4143.
    • (2009) Blood , vol.113 , pp. 4137-4143
    • Knop, S.1    Gerecke, C.2    Liebisch, P.3
  • 16
    • 42649116903 scopus 로고    scopus 로고
    • Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): Analysis from MM-009 and MM-010 randomized phase III clinical trials
    • ASH Annual Meeting Abstracts
    • Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting Abstracts). 2006;108:3554.
    • (2006) Blood , vol.108 , pp. 3554
    • Chanan-Khan, A.A.1    Yu, Z.2    Weber, D.3
  • 17
    • 34547625141 scopus 로고    scopus 로고
    • Lenalidomide (Revlimid) costicosteroid in elderly patients with relapsed/refractory multiple myeloma
    • ASH Annual Meeting Abstracts
    • Reece D, Masih-Khan, Chen C, et al. Lenalidomide (Revlimid) costicosteroid in elderly patients with relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108:3550.
    • (2006) Blood , vol.108 , pp. 3550
    • Reece, D.1    Masih-Khan2    Chen, C.3
  • 18
    • 39149109289 scopus 로고    scopus 로고
    • Prevention of thalidomide and lenalidomide associated trombosis in myeloma
    • International Myeloma Working Group
    • Palumbo A, Rajkumar SV, Dimopoulus MA, et al. International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated trombosis in myeloma. Leukemia. 2008;22:414-423.
    • (2008) Leukemia , vol.22 , pp. 414-423
    • Palumbo, A.1    Rajkumar, S.V.2    Dimopoulus, M.A.3
  • 19
    • 0037208595 scopus 로고    scopus 로고
    • Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
    • Weber D, Rankin K, Gavion M, Dalasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
    • (2003) J Clin Oncol , vol.21 , pp. 16-19
    • Weber, D.1    Rankin, K.2    Gavion, M.3    Dalasalle, K.4    Alexanian, R.5
  • 21
    • 0035469858 scopus 로고    scopus 로고
    • Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    • Zangari M, Anaissie E, Barlogi B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
    • (2001) Blood , vol.98 , pp. 1614-1615
    • Zangari, M.1    Anaissie, E.2    Barlogi, B.3
  • 22
    • 33745590139 scopus 로고    scopus 로고
    • Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis [5]
    • DOI 10.1182/blood-2006-01-0154
    • Zonder JA, Barlogie B, Durie DG, Mc Coy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood (ASH Annual Meeting Abstracts). 2006;108:403. (Pubitemid 43990659)
    • (2006) Blood , vol.108 , Issue.1 , pp. 403
    • Zonder, J.A.1    Barlogie, B.2    Durie, B.G.M.3    McCoy, J.4    Crowley, J.5    Hussein, M.A.6
  • 23
    • 79959765455 scopus 로고    scopus 로고
    • Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens
    • ASH Annual Meeting Abstracts
    • Brandenburg NA, Goss TF, Knight T, Xu X, Knight RD. Evaluation of the relationship between venous thromboembolism risk factors and the use of antithrombotic prophylaxis in multiple myeloma patients treated with thalidomide and dexamethasone combination regimens. Blood (ASH Annual Meeting Abstracts). 2008;112:2369.
    • (2008) Blood , vol.112 , pp. 2369
    • Brandenburg, N.A.1    Goss, T.F.2    Knight, T.3    Xu, X.4    Knight, R.D.5
  • 24
    • 73949154067 scopus 로고    scopus 로고
    • Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone
    • Zangari M, Tricot G, Poavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high dose dexamethasone. J Clin Oncol. 2009;28:132-135.
    • (2009) J Clin Oncol , vol.28 , pp. 132-135
    • Zangari, M.1    Tricot, G.2    Poavaram, L.3
  • 25
    • 79959753459 scopus 로고    scopus 로고
    • Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: Aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors
    • ASH Annual Meeting Abstracts
    • Wright JA, Weber D, Thomas SK, et al. Characteristics of patients experiencing thomboembolic events during treatment for multiple myeloma: aspirin may not be adequate thromboprophylaxis in patients with multiple risk factors. Blood (ASH Annual Meeting Abstracts). 2007;110:1882.
    • (2007) Blood , vol.110 , pp. 1882
    • Wright, J.A.1    Weber, D.2    Thomas, S.K.3
  • 26
    • 57049113927 scopus 로고    scopus 로고
    • Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
    • Klein U, Kosely F, Hillegab J, et al. Effective prophylaxis with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol. 2009:88:67-71.
    • (2009) Ann Hematol , vol.88 , pp. 67-71
    • Klein, U.1    Kosely, F.2    Hillegab, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.